



# PRELIMINARY PROGRAM

**October 12, 2020**

8.00- 8.10 *Welcome and Introduction*

**8.10 – 9.20 Session 1**

## *FI Epidemiology and Diagnosis*

- Epidemiology and diagnosis of FI
- How to measure the FI severity?
- Double fecal/urinary incontinence: condition for a MDT

*Discussion*

**9.20 – 12.10 Session 2**

## *FI Treatment (1) – From Conservative Management to Nerve Stimulation*

- Conservative management of FI: when primary approach? When supportive treatment?
- Pelvic floor rehabilitation in FI: principles and indications
- The agony of sphincteroplasty: is it justified to abandon it?
- How to avoid a failure of sphincteroplasty

*Coffee break*

- Sacral nerve stimulation in FI: the best indications today
- Different ways of nerve stimulation for FI: are they equally effective than SNS?
- News in the pelvic floor nerve stimulation

*Discussion*

**12.10 – 12.40**

## *Best Oral Presentations (part 1)*

- Selected Oral Presentation 1.1
- Selected Oral Presentation 1.2
- Selected Oral Presentation 1.3

*Lunch*

**13.30 – 14.00**

## **Lecture:**

Status-of-art of FI treatment: progression or regression?

## **14.00 – 16.45 Session 3**

### **FI Treatment (2) – Low and High Severity FI and Special Conditions**

- When FI treatment can be easier and when more challenging?
- SphinKeeper: a safe procedure with great potentials
- Severe FI: are we raising our hands today?
- Current efficacy of different options in treating FI
- FI in treating perianal fistulas
- FI after anterior resection of the rectum
- Prevention of LARS: Is TaTME better than traditional low anterior resection?
- Illusions and delusions for patients with FI
- Future in the management of FI

*Discussion*

## **16.45 – 17.15**

### **Best Oral Presentations (part 2)**

- Selected Oral Presentation 2.1
- Selected Oral Presentation 2.2
- Selected Oral Presentation 2.3

## **17.15 – 18.00 Consultant corner 1**

### **Therapeutic integration in FI**

**October 13, 2020**

**8.15 – 10.30 Session 4**

**ODS Epidemiology and Diagnosis**

- How pelvic floor anatomy can influence management of disorders
- Clinical assessment and classification of patients with ODS: is it only a matter of experience?
- ODS symptoms and anatomical abnormalities: which first? Modern answers to an old question
- FLuro, MRI and Echo defecography: can their use and interpretation templates for ODS be standardized?
- Radiologic prognostic factors in the assessment of ODS
- ODS: a “double-meaning” syndrome
- Severity scores and QoL assessment: how can they influence the ODS management?

*Discussion*

*Coffee break*

**11.00 – 11.30**

**Lecture:**

ODS management: A “holistic” approach to an “all-in-one” condition

**11.30 – 15.00 Session 5**

**ODS Treatment (1) – Different Approaches to Choose**

- Conservative management of ODS: when and how?
- Milestones and pitfalls of surgical approach to ODS
- Transvaginal approach to rectocele: why, when and how?
- I would prefer transanal approach: why, when and how?
- I would prefer abdominal approach: why, when and how?

*Lunch*

- Use of meshes in treating ODS
- Pros and contras in open, laparoscopic, robotic abdominal surgery
- POPS ± Transanal Mucosal Rectopexy: strengths and results
- Management of pelvic organ prolapse: MDT does it better! Is it true? When applicable?

*Discussion*

**15.00 – 15.45 Consultant corner 2**

**Management of FI-ODS Coexistence**

## **15.45 – 17.15 Session 6**

### **ODS Treatment (2) – Prevention and Management of Complications and Outcome Predictive Factors**

- Complications of abdominal approach to ODS: how to avoid and how to eliminate?
- Complications of transanal approach to ODS: how to avoid and how to eliminate?
- How much do complications affect the choice of ODS treatment?
- Positive and negative predictive factors of therapeutic success
- Investigation and management of the patient with persistent ODS after surgery

*Discussion*

## **17.30 Closure**

## **FACULTY**

1. **ABBAS M.A. - U.A.E.**
2. **ADAMINA M. - Switzerland**
3. **BIONDO S. - Spain**
4. **BORDEIANOU L. - USA**
5. **BRESLER L. - France**
6. **CAMPAGNA G. - Italy**
7. **CHRISTENSEN P. - Denmark**
8. **D'HOORE A. - Belgium**
9. **DIOMEDE F. - Italy**
10. **ERCOLI A. - Italy**
11. **ESPIN E. - Spain**
12. **FALLETTO E. - Italy**
13. **FAUCHERON J.L. - France**
14. **GAGLIARDI G. - USA**
15. **GIANFREDA V. - Italy**
16. **HAHNLOSER D. - Switzerland**
17. **ISBERT C. - Germany**
18. **JONES O. - UK**
19. **KNOWLES C. - UK**
20. **LEHUR P.A. - France**
21. **LINDSEY I. - UK**
22. **LUNDBY L. - Denmark**
23. **MATZEL K. - Germany**
24. **MUNOZ-DUYOS A. - Spain**
25. **MURPHY M. - USA**
26. **NALDINI G. - Italy**
27. **O'CONNELL P.R. - Ireland**
28. **PARELLO A. - Italy**
29. **PERSIANI R. - Italy**
30. **RATTO C. - Italy**
31. **SCHERER R. - Germany**
32. **SICA G. - Italy**
33. **SILERI P. - Italy**
34. **SOLIGO M. - Italy**
35. **SPINELLI A. - Italy**
36. **TSARKOV P. - Russia**
37. **TULINA I. - Russia**
38. **VISCARDI A. - Italy**
39. **WARUSAVITARNE J. - UK**
40. **YAMANA T. - Japan**